Medigene achieves positive formulation study results for RhuDex® and announces phase II proof-of-concept study for the treatment of autoimmune diseases
03:31 EDT 21 Jun 2012 | Thomson Reuters
This article has expired, however you can still
download the PDF.
Preview:
MediGene AG /
Medigene achieves positive formulation study results for RhuDex® and announces
phase II proof-of-concept study for the treatment of autoimmune diseases
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible fo...
Other Sources for this Article
More From BioPortfolio on "Medigene achieves positive formulation study results for RhuDex® and announces phase II proof-of-concept study for the treatment of autoimmune diseases "
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
